Bone metastases arise most commonly in patients suffering from breast, prostate, kidney or lung cancer.^[@bibr1-2058-5241.1.000008]^ Two-thirds of all patients dying of cancer reportedly develop bone metastases;^[@bibr2-2058-5241.1.000008]^ however, a modern, image-based study would probably present an even higher number. Due to constantly improving treatments, the duration of the palliative phase is prolonged. Longer survival unfortunately gives each patient more time to develop metastases.

Bone metastases of the long bones may lead to pain, pathological fractures, immobility, decreased functioning, and hypercalcaemia. Over half of patients experience clinical symptoms for which treatment is required,^[@bibr3-2058-5241.1.000008]^ of whom only a minority are surgically treated.^[@bibr4-2058-5241.1.000008]^ In the long bones, pain is the most common symptom, followed by impending or actual pathological fractures in 10%-25% of patients.^[@bibr5-2058-5241.1.000008]^ Pathological fractures of the femur, 75% of which present in the proximal part, are roughly 3.5 times as common as fractures of the humerus.^[@bibr6-2058-5241.1.000008]^

This review discusses the local management of (impending) pathological fractures of the long bones, with focus on surgical treatment strategies.

Diagnosis and evaluation {#section1-2058-5241.1.000008}
========================

For successful management, the following adage should be followed: stop; think and stage; act. The most important information is gathered with the following four questions and flowchart ([Fig. 1](#fig1-2058-5241.1.000008){ref-type="fig"}).

![Flowchart of diagnostic tests.\
\*Survival prediction according to primary tumour type, patient performance score, visceral or cerebral metastases.^[@bibr19-2058-5241.1.000008]^\
\*\*Fracture risk according to axial cortical involvement or circumferential cortical involvement of \> 50%.^[@bibr13-2058-5241.1.000008]^](eor-1-136-g001){#fig1-2058-5241.1.000008}

What is the origin of the lesion? {#section2-2058-5241.1.000008}
---------------------------------

A bone lesion with unknown aetiology is a primary bone tumour until proven otherwise. Denying this possibility might deprive patients of correct and curative treatments. If the patient has no history of malignancy, a (PET-)CT scan of the chest and abdomen should be performed. In case no primary tumour is visible, a core needle biopsy of the bone lesion should be performed for histological identification before treatment is engaged. When the patient has already known malignancy, but has no previous metastases and the lesion is solitary, a biopsy should be considered. In cases of multiple lesions and a malignancy at high risk for developing metastases (e.g. lung cancer), generally no additional histological confirmation is necessary.

What is the dissemination status? {#section3-2058-5241.1.000008}
---------------------------------

The presence of other disease localisations influences the treatment strategy. Bone dissemination can be grouped into three categories: solitary lesion, oligometastases (between two and four bone metastases), or diffuse. Solitary lesions can, in some cases (such as primary kidney cancer or bone sarcoma), be treated with curative, albeit generally palliative, intent.^[@bibr7-2058-5241.1.000008]^ Defining a difference between oligometastases and diffuse metastases throughout the skeleton is a relatively new concept. Especially for kidney and breast cancer patients, it is hypothesised that a more aggressive local treatment in the case of oligometastases might improve survival.^[@bibr8-2058-5241.1.000008]^ In the past, the principal examination to assess the bone dissemination status was a total-body bone scintigraphy (technetium-99m or fluoride-18 scan). Currently the use of PET-CT is accelerating due to its increased accessibility and superior sensitivity and specificity to bone scintigraphy.^[@bibr9-2058-5241.1.000008]^ Additionally, PET-CT provides information on other (visceral) disease localisations. If PET-CT is unavailable, then an additional CT of the thorax/abdomen should be considered to analyse visceral dissemination.

What is the general health of the patient? {#section4-2058-5241.1.000008}
------------------------------------------

The general health status can be deduced from the patient history (nutritional status, weight loss and cognitive status, for example). Dehydration, thirst or drowsiness can suggest hypercalcaemia and blood tests (serum calcium and albumin) should be performed.

If surgery is planned, laboratory studies should include a complete differential blood-cell count, erythrocyte sedimentation rate, C-reactive protein, electrolyte count (sodium, potassium), and serum alkaline phosphate.

What is the local status of the involved bone? {#section5-2058-5241.1.000008}
----------------------------------------------

In daily practice, bi-planar conventional radiographs of the whole affected long bone are mandatory to evaluate the extent of the cortical destruction of the involved bone lesion and whether other adjacent bone lesions are present. The cortical destruction is a measure for estimating the fracture risk. A CT scan is a more precise alternative for obtaining this information; however, routine use of CT scans is less practical and more expensive than radiographs and thus not advised as a primary imaging modality.

The information gathered with the standard work-up provides the basis for staging of the patient and determining the treatment strategy. The first step is the decision in a multi-disciplinary meeting on whether surgery is required. Radiotherapy is the treatment of choice for small lesions, while surgery is indicated for actual fractures. The difficulty lies in the group of patients with larger lesions and an uncertain risk of fracturing. All treatments aim to maintain optimal, pain-free function of the extremities and should ensure direct weight bearing and mobility. Two important principles should be adhered to:

-   *Prophylactic stabilisation of bone should be performed if there is a substantial risk of fracturing.* If the risk of fracturing is low, the appropriate treatment is radiotherapy. While there is general consensus about the advantages of operating on impending fractures over actual fractures, a clear, international definition of 'a substantial risk' has not been defined.^[@bibr10-2058-5241.1.000008]^ To prevent over- and under-treatment, a careful balance between the advantages of a prophylactic treatment *versus* the risks of surgery and disadvantages of over-treatment for the patient has to be made. Multiple different factors for an impending fracture have been described, such as pain, size, site and lesion aspect.^[@bibr11-2058-5241.1.000008],[@bibr12-2058-5241.1.000008]^ However, because these factors are based on retrospective research, their predictive value is low.^[@bibr10-2058-5241.1.000008]^ Based on prospective research, we advise the use of the axial cortical involvement of \> 30 mm and a circumferential cortical involvement of \> 50% as predictive factors for fracturing (see [Fig. 2](#fig2-2058-5241.1.000008){ref-type="fig"}).^[@bibr13-2058-5241.1.000008]^ Although the future of fracture risk analysis is CT-based,^[@bibr14-2058-5241.1.000008]^ the axial cortical involvement is the most practical tool to use if only conventional radiographs are available.

-   *The selected rigid fixation should be durable for the remaining lifetime of the patient, while the recovery and rehabilitation time should not exceed the life expectancy*. Survival can range from days to many years depending primarily on the primary tumour type. Median survival for patients with bone metastases from lung cancer is three months, while this extends to ten months for prostate and 17 months for breast cancer.^[@bibr15-2058-5241.1.000008]^ Multiple factors are considered prognostic for survival besides primary tumour type and various prognostic models based on these factors have been designed, as shown in [Table 1](#table1-2058-5241.1.000008){ref-type="table"}.^[@bibr4-2058-5241.1.000008],[@bibr15-2058-5241.1.000008],[@bibr20-2058-5241.1.000008]^ We advise the prediction of survival according to a simple and straightforward model, including primary tumour type, performance score, and the presence of visceral or cerebral metastases ([Fig. 3](#fig3-2058-5241.1.000008){ref-type="fig"}).^[@bibr19-2058-5241.1.000008]^

![Measurement of metastatic lesions in the femur (in mm): largest axial measurement of lesion (L-lesion), largest transverse extension of the lesion (W-lesion), largest axial cortical involvement (L-cort).\
(Reprinted with permission from: van der Linden YM, Kroon HM, Dijkstra SPDS, et al. Simple radiographic parameter predicts fracturing in metastatic femoral bone lesions: results from a randomised trial. *Radiotherapy and Oncology* 2003;69:21-31).](eor-1-136-g002){#fig2-2058-5241.1.000008}

###### 

Prognostic factors for survival in patients with bone metastases

                                BAU        FOR        RAT        BOL       KAT        WES         JAN
  ----------------------------- ---------- ---------- ---------- --------- ---------- ----------- -----
  Site of bone metastases       Skeletal   Skeletal   Skeletal   Spinal    Skeletal   Skeletal    LB
  Number of patients            241        189        1195       1043      350        1157        927
  Primary treatment             Sur        Sur        Sur        Con/Sur   Con/Sur    Con         Sur
  Primary tumour                X          X          X          X         X             X^1+2^   X
  Performance status                                  X          X         X            X^1+2^    
  Visceral metastasis           X          X          X          X         X          X^2^        X
  Cerebral metastases           X                                X         X                      
  Lymph node metastases                    X                                                      
  Number of metastases          X                     X                    X                      X
  Chemotherapy                                                             X                      
  Age                                                                                             X
  Comorbidity                                                                                     X
  BMI \< 18.5 kg/m^2^                                                                             X
  Laboratory results                       X                               X                      X
  Gender                                   X                                          X^2^        
  Pathologic fracture           X          X                                                      
  Surgeons' estimate survival              X                                                      
  Patient reported pain                                                               X^2^        

BAU: Bauer 1995^[@bibr17-2058-5241.1.000008]^; FOR: Forsberg 2011^[@bibr18-2058-5241.1.000008]^; RAT: Ratasvuori 2013^[@bibr19-2058-5241.1.000008]^; BOL: Bollen 2014^[@bibr20-2058-5241.1.000008]^; KAT: Katagiri revised 2014^[@bibr5-2058-5241.1.000008]^; WES: Westhoff 2014^[@bibr16-2058-5241.1.000008]^, 1 simplified model, 2 complex model; JAN: Janssen 2015^[@bibr24-2058-5241.1.000008]^. Skeletal: all sites; Spinal: axial skeleton; LB: long bones; Con: chemo/radiotherapy; Sur: surgery.

![Prediction model for survival.\
Category (a-d) indicates expected survival in months.\
(Reprinted with permission from: Bollen L, van der Linden YM, Pondaag W, et al. Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1043 patients. *Neuro-Oncology* 2014;16:991-98.)](eor-1-136-g003){#fig3-2058-5241.1.000008}

If survival is less than six weeks, the possible benefits of surgical intervention need to be strongly considered and generally care with conservative measures should be sought (such as care at a hospice). If surgical intervention is absolutely required, it should be as minimally invasive as possible with a short recovery time. For patients with an expected short-term survival (between six weeks and six months), more invasive procedures are warranted. However, the use of extensive reconstructions or large, complication-prone prostheses should not be pursued. Long-term survival (expected survival \> six months) justifies and requires comprehensive surgery.

Radiotherapy {#section6-2058-5241.1.000008}
============

Palliative radiotherapy for painful bone metastases is well established and provides an effective symptomatic treatment. The overall response rate is 60%, depending on the primary tumour and the expected survival time.^[@bibr21-2058-5241.1.000008]^ A single fraction of 8 Gy is presently considered standard treatment for painful lesions with a low risk of fracture. If pain is recurrent after a single fraction, a second or third fraction of 8 Gy can be given without many treatment side-effects. For large lesions with extensive osseous destruction, it is believed that a higher total dose given in a fractionated scheme will lead to a higher tumour response with remineralisation to strengthen the bone and postpone the occurrence of a fracture.^[@bibr22-2058-5241.1.000008]^

Post-operative radiotherapy is commonly advised as prophylaxis for tumour progression and implant failure.^[@bibr23-2058-5241.1.000008]^ However, this is not evidence-based and further prospective research should be performed before statements can be made concerning the effectiveness of adjuvant radiotherapy for all patients.

Surgery {#section7-2058-5241.1.000008}
=======

Differing skeletal locations, life expectancies, patient characteristics (for example obesity) and types of fractures lead to variation in treatments. The planned procedure generally entails an intra-lesional approach. A more extensive procedure is unnecessary for oncological control. An en-bloc resection is only indicated when there is vast destruction of bone or in the rare occasion of a curative intent of the procedure. In patients with actual fractures due to metastases of kidney and thyroid cancer, pre-operative embolisation of the metastasis is advised to prevent excessive peri-operative blood loss.^[@bibr24-2058-5241.1.000008]^ Surgery should be performed within 72 hours following embolisation.

For all pathological fractures of the long bones, three principal surgical treatment options exist: intramedullary nail, plate, or (endo) prosthesis. Intramedullary nails offer several advantages: they protect a long segment of bone, the necessary dissection is relatively small, blood supply to the periosteum is preserved, and rigid fixation can be achieved by locking with proximal and distal interlocking screws, and/or by using bone cement surrounding the nail.^[@bibr25-2058-5241.1.000008]^ All intramedullary nails need distal locking to provide rotation stabilisation and prevent failure of fixation.^[@bibr26-2058-5241.1.000008]^ Proximal fixation can be achieved with standard screws or with an interlocking lag screw or helical blade, for both the femur and the humerus. The large lag screw or helical blade allows for a stronger construct due to the increased surface area contact. An intramedullary nail allows for immediate and unrestricted stability. With time, however, intramedullary nails without cement augmentation are at risk of failure, because they are load-sharing devices instead of load-bearing devices. Other disadvantages are the need for adequate bone stock at the site of the locking screw(s) and its inapplicability for lesions close to the joint.

Plate fixation offers several advantages: damage to the muscle cuff can be avoided, very distal fractures can also be adequately fixed, and rigid fixation is possible with locking screws. In addition, the open approach provides good access and visualisation for curettage, fracture reduction and reposition, and application of adjuvant cement. The downsides of using a plate include the large incision needed, a longer surgical procedure and the lack of prophylactic fixation of the entire bone. Prosthetic reconstructions (endoprostheses, segmental prostheses, hemi- and total joint arthroplasty) provide immediate stability, independent of the degree of fracture healing, and the risk of local progression or implant failure is minimised.^[@bibr27-2058-5241.1.000008]^ The principal drawback of this method is the high risk of complications.^[@bibr28-2058-5241.1.000008]^ The surgery is extensive, muscles need detaching and reattaching, and it is associated with increased blood loss.^[@bibr29-2058-5241.1.000008]^ In addition, if post-operative radiotherapy is believed to be an important adjuvant treatment, endoprostheses should not be used due to radiotherapy-induced osteoporosis and impaired bone healing, leading to inadequate screw fixation.^[@bibr30-2058-5241.1.000008]^ The high costs of endoprostheses used to be a significant factor to take into account. However, manufacturers are developing cheaper endoprostheses indicated especially for metastatic disease so this has become a less decisive aspect.

Each region has its own options and treatment strategies, as shown in [Tables 2](#table2-2058-5241.1.000008){ref-type="table"} and [3](#table3-2058-5241.1.000008){ref-type="table"} for the femur and humerus, respectively. If the tibia, ulna, or radius is involved, treatment strategies for the humerus should be followed.

###### 

Surgical treatment of metastatic lesions of the femur

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Femur                             Survival                                                                                           Actual fracture                                                       Impending fracture                                                                                                                             
  --------------------------------- -------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------- --------------------------------------------------------------------------------------
  **Acetabulum largely affected**   THP                                                                                                THP\                                                                  THP                                                                    THP\                                                                    
                                                                                                                                       or pAMP +\                                                                                                                                   or pAMP+ C                                                              
                                                                                                                                       C                                                                                                                                                                                                                    

  **Head / neck**                                                                                                                      Hemi + C                                                              Hemi + C                                                               Hemi + C                                                                Hemi + C

  **Inter / sub trochanteric**      Adequate bone stock (small / solitary[\*](#table-fn4-2058-5241.1.000008){ref-type="table-fn"})     IMN                                                                   IMN                                                                    IMN                                                                     IMN

                                    Inadequate bone stock (large / multiple[\*](#table-fn4-2058-5241.1.000008){ref-type="table-fn"})   IMN                                                                   PF-MTP + C                                                             IMN                                                                     IMN\
                                                                                                                                                                                                                                                                                                                                                            or PF-MTP + C

  **Diaphysis**                     Small / solitary[\*](#table-fn4-2058-5241.1.000008){ref-type="table-fn"}                           Plate^[\#](#table-fn3-2058-5241.1.000008){ref-type="table-fn"}^ + C   Plate^[\#](#table-fn3-2058-5241.1.000008){ref-type="table-fn"}^ + C\   Plate^[\#](#table-fn3-2058-5241.1.000008){ref-type="table-fn"}^ + C\    IMN\
                                                                                                                                                                                                             or SP                                                                  or IMN                                                                  or SP

                                    Large / multiple[\*](#table-fn4-2058-5241.1.000008){ref-type="table-fn"}                           IMN                                                                   IMN\                                                                   IMN                                                                     IMN\
                                                                                                                                                                                                             or SP                                                                                                                                          or SP

  **Metaphysis**                                                                                                                       Plate^[\#](#table-fn3-2058-5241.1.000008){ref-type="table-fn"}^ + C   Plate^[\#](#table-fn3-2058-5241.1.000008){ref-type="table-fn"}^ + C\   (Plate^[\#](#table-fn3-2058-5241.1.000008){ref-type="table-fn"}^ +) C   IMN
                                                                                                                                                                                                             or DF-MTP                                                                                                                                      

  **Condyles**                      Small / solitary[\*](#table-fn4-2058-5241.1.000008){ref-type="table-fn"}                           Plate^[\#](#table-fn3-2058-5241.1.000008){ref-type="table-fn"}^+ C    DF-MTP                                                                 (Plate^[\#](#table-fn3-2058-5241.1.000008){ref-type="table-fn"}^ +) C   (Plate^[\#](#table-fn3-2058-5241.1.000008){ref-type="table-fn"}^ +) cement or DF-MTP

                                    Large / multiple[\*](#table-fn4-2058-5241.1.000008){ref-type="table-fn"}                           DF-MTP                                                                DF-MTP                                                                 DF-MTP                                                                  DF-MTP
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All types of treatments are intralesional. Adjuvant cement (C; polymethylmetacrylate) with intramedullary nails is indicated if expected survival is long or if the bone stock is inadequate. Treat sites with impaired strength with cement, i.e. at screw fixation through nail and at metastatic lesion.

The use of locked plate-screw plate fixations generally makes double plating unnecessary. If conventional plates are used, double plating should be considered.

Number of metastases in the affected region.

THP = total hip arthroplasty;

Hemi = hemi hip arthroplasty;

pAMP = peri-acetabular modular prosthesis;

IMN = antegrade placed intramedullary nail (reconstruction type);

PF-MTP = proximal femur modular tumour prosthesis;

DF-MTP = distal femur modular tumour prosthesis;

SG = segmental prosthesis.

###### 

Surgical treatment of metastatic lesions of the humerus

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Humerus                        Survival                                                                    Actual fracture                                                         Impending fracture                                                                                                                                    
  ------------------------------ --------------------------------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------------- -----------------------------------------------------------------------------
  **Proximal -- humerus head**   Adequate bone stock                                                         IMN + HB                                                                IMN + HB                                                                IMN + HB                                                                      IMN + HB

                                 Inadequate bone stock                                                       Plate^[\#](#table-fn13-2058-5241.1.000008){ref-type="table-fn"}^ + C    IMN + HB + C\                                                           IMN + HB                                                                      IMN + HB + C
                                                                                                                                                                                     or HSP + C                                                                                                                                            

  **glenoid**                                                                                                Cement                                                                  Cement                                                                  Cement                                                                        Cement

  **Shaft**                      Small / solitary[\*](#table-fn14-2058-5241.1.000008){ref-type="table-fn"}   Plate^[\#](#table-fn13-2058-5241.1.000008){ref-type="table-fn"}^ + C\   Plate ^[\#](#table-fn13-2058-5241.1.000008){ref-type="table-fn"}^+ C\   IMN                                                                           IMN\
                                                                                                             or IMN                                                                  or IMN\                                                                                                                                               or SP
                                                                                                                                                                                     or SP                                                                                                                                                 

                                 Large / multiple[\*](#table-fn14-2058-5241.1.000008){ref-type="table-fn"}   IMN                                                                     IMN\                                                                    IMN                                                                           IMN\
                                                                                                                                                                                     or SP                                                                                                                                                 or SP

  **Distal**                     All sizes                                                                   Plate^[\#](#table-fn13-2058-5241.1.000008){ref-type="table-fn"}^ + C    Plate^[\#](#table-fn13-2058-5241.1.000008){ref-type="table-fn"}^ + C    IMN or Plate^[\#](#table-fn13-2058-5241.1.000008){ref-type="table-fn"}^ + C   IMN or Plate^[\#](#table-fn13-2058-5241.1.000008){ref-type="table-fn"}^ + C
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All types of treatments are intralesional. Adjuvant cement (C; polymethylmetacrylate) with intramedullary nails is indicated if expected survival is long or if the bone stock is inadequate. Treat sites with impaired strength with cement, i.e. at screw fixation through nail and at metastatic lesion.

The use of locked plate-screw plate fixations generally makes double plating unnecessary. If conventional plates are used, double plating should be considered.

Number of metastases in the affected region.

IMN = intramedullary nail; SP = segmental prosthesis;

HB = helical blade; HSP = hemi shoulder prosthesis.

Despite the extensive period of time during which bone metastases have been treated, no randomised controlled trials have been performed to evaluate the best surgical procedures for each setting.^[@bibr31-2058-5241.1.000008]^ Therefore, the recommended procedures are mostly based on retrospective observational studies and clinical experience.

Femur {#section8-2058-5241.1.000008}
-----

Pathological fractures of the proximal femur are most common in the femoral neck, followed by the sub- and intertrochanteric regions, the diaphysis, and distal femur.^[@bibr32-2058-5241.1.000008]^ The different treatment approaches are given in [Table 2](#table2-2058-5241.1.000008){ref-type="table"}.

In general, the treatment strategy of the femur depends on the involvement of the acetabulum. If the acetabulum is grossly affected, a (modular) total hip arthroplasty (THA) with cup augmentation is indicated. When placing a THA for metastatic disease, a relatively high risk of dislocation should be acknowledged. The muscular cuff is very likely weak or insufficient due to previous systemic treatment, radiotherapy or immobilisation. To minimise the risk of hip dislocation we recommend a dual-mobility cup. In cases with extensive involvement of the proximal femur and acetabulum and where long-term survival is expected, a hemi-pelvic endoprosthesis is more suitable. If the acetabulum is unaffected or marginally affected (less than one-third of the circumference), the strategy depends on the localisation.

For pathological fractures of the femoral head and neck a (cemented) hemi-arthroplasty is recommended. The secondary degenerative changes associated with hemi-arthroplasties will rarely present.^[@bibr33-2058-5241.1.000008]^ A long stem provides prophylactic stabilisation of the entire femur shaft, but is accompanied with higher risks of complications such as thrombo-embolic events.^[@bibr34-2058-5241.1.000008]^ It is unclear in literature whether a long stem should be routinely placed.^[@bibr35-2058-5241.1.000008]^

The optimal treatment of pathological fractures of the trochanteric region is a frequently discussed issue. The options consist of intramedullary reconstruction nails and prosthetic reconstruction, but there is poor evidence as to which serves patients better.^[@bibr36-2058-5241.1.000008]^ The decision is primarily based on the quality of bone stock. If the bone stock is sufficient to create a stable situation (i.e. a small or solitary lesion), an intramedullary reconstruction nail including femoral neck and head fixation is advised ([Fig. 4](#fig4-2058-5241.1.000008){ref-type="fig"}) for both actual and impending fractures as for both patients with a short and long expected survival.^[@bibr37-2058-5241.1.000008]^ Cement can be considered to prevent mechanical failure, especially if the expected survival is long.

![Patient with osseous and pulmonary metastases from breast cancer. Progression of the proximal femur lesion over one month with subtrochanteric pathological fracture as a result. Expected survival \> 6 months. A PF-MTP with cement was placed.](eor-1-136-g004){#fig4-2058-5241.1.000008}

If there is insufficient bone stock and doubt exists concerning the durability of the screw fixation in the femoral head, the choice of treatment needs more careful consideration. For patients with short-term survival, an intramedullary reconstruction nail with cement will provide sufficient stability, despite poor bone stock and irrelevant to the type of fracture. Patients with long-term expected survival and an actual fracture should be treated with a proximal femur modular tumour-prosthesis (PF-MTP) to provide an adequately durable situation ([Fig. 4](#fig4-2058-5241.1.000008){ref-type="fig"}).^[@bibr38-2058-5241.1.000008]^ A PF-MTP can also be considered if patients with a long-term survival present with an impending fracture; however, it might not be necessary, and intramedullary nailing with cement can provide sufficient stabilisation.

Pathological fractures of the diaphysis are commonly treated with intramedullary nails or plate osteosynthesis. If multiple lesions exist throughout the diaphysis, an intramedullary nail is recommended. Large lesions (\> 6 cm) can be curetted prior to stabilisation and adjuvant cement will further stabilise the nail ([Fig. 5](#fig5-2058-5241.1.000008){ref-type="fig"}). An intramedullary nail is also recommended for an impending fracture through a small or solitary lesion. However, if an actual fracture presents through a small lesion, open reduction and plate fixation with adjuvant cement is an adequate option, irrespective of the expected survival. In cases with a long survival and solitary metastases (for example, renal cell) or very large and destructive diaphyseal lesions, a segmental prosthesis of the diaphysis is an option.

![Patient with osseous and cerebral metastases from melanoma. Pathological diaphyseal femoral fracture after turning in bed. Expected survival \< 6 months. Fracture stabilisation with intramedullary nail with curettage and augmentation of the lesion.](eor-1-136-g005){#fig5-2058-5241.1.000008}

The treatment of pathological fractures of the distal femur generally consists of plating with adjuvant cement. However, if the condyles or metaphyses are largely affected the fixation of a plate is often impossible. In this case a distal femur modular tumour-prosthesis (DF-MTP) is recommended ([Fig. 6](#fig6-2058-5241.1.000008){ref-type="fig"}). A DF-MTP should also be considered for patients with long-term survival and fractures due to distal or metaphyseal lesions. If there is no actual fracture yet and survival is short-term, cement injection only, or in combination with radio-frequency ablation, can be sufficient. However, if long-term survival is expected this might not provide sufficient prophylactic stabilisation for an impending fracture, and an intramedullary nail with cement in the lesion or a DF-MTP should be considered.

![Patient with solitary bone metastasis from non small cell lung carcinoma (diagnosed and treated 4.5 years ago). Metastasis of distal femur with extensive destruction 1.5 years after radiotherapy for this lesion. Expected survival \> 6 months. Resection and reconstruction with DF-MTP.](eor-1-136-g006){#fig6-2058-5241.1.000008}

Humerus {#section9-2058-5241.1.000008}
-------

After the femur, the humerus is the second most commonly affected long bone by metastases.^[@bibr39-2058-5241.1.000008]^ The mainstay treatment is rigid surgical stabilisation because of a high incidence of nonunion and inadequate relief of pain with conservative treatment.^[@bibr40-2058-5241.1.000008]^ Although the upper extremities are not primarily weight-bearing, the proximal humerus is subject to rotational and bending forces due to the action of the rotator cuff, deltoid, pectoralis major and latissimus dorsi muscles. This demands great torsional strength of any kind of implant.^[@bibr41-2058-5241.1.000008]^ An overview of treatment options is given in [Table 3](#table3-2058-5241.1.000008){ref-type="table"}.

For the humeral head, options consist of plate fixation or a cemented hemi-arthroplasty. The latter should be considered for actual fractures in patients with long-term survival needing elaborate reconstruction due to inadequate bone stock. However, if the expected survival is short, there is adequate bone stock, or there is only an impending fracture one should refrain from being too invasive. Lesions in the proximal humerus generally require curettage and augmentation to prevent rapid local progression and loosening of the osteosynthesis.^[@bibr42-2058-5241.1.000008]^ Therefore plating is often the fixation method of choice. This gives immediate rigidity and allows for unrestricted function quickly post-operatively.^[@bibr43-2058-5241.1.000008]^ Fixation with an ante-grade intramedullary nail and helical blade (or screws) strengthened with adjuvant cement is also possible; however, this is more appropriate in cases with extended involvement of the shaft than in cases with only proximal involvement. Total shoulder prostheses are not advised for bone metastases due to the high rate of complications, mainly recurring dislocations. If the glenoid is affected together with the proximal humerus, this can be filled up with cement.

Fractures affecting the humeral shaft can be treated with plate fixation or intramedullary fixation ([Fig. 7](#fig7-2058-5241.1.000008){ref-type="fig"}, a and b; respectively). In the region between 2-3 cm distal to the greater tuberosity and 5 cm proximal to the olecranon fossa, intramedullary nails achieve adequate stabilisation.^[@bibr44-2058-5241.1.000008]^ Depending on the lesion size, adjuvant cement might be required to provide adequate fixation. If an open approach is chosen for augmentation, a plate fixation can then also be chosen. Impending fractures of the shaft can always be treated with intramedullary nails. In patients with short expected survival or high surgical risks (ASA 4), percutaneous, photodynamic intramedullary stabilisation systems can also be an option to examine.^[@bibr45-2058-5241.1.000008]^ The humeral diaphysis can also be treated with segmental prostheses according to the indications in the femur diaphysis.^[@bibr46-2058-5241.1.000008]^

![a) Patient with osseous metastases from lung carcinoma. Pathological fracture of proximal humerus diaphysis. Expected survival \< 6 months. Plate fixation with cement. b) Patient with osseous metastases from renal cell carcinoma. Pathological fracture of proximal humerus diaphysis. Expected survival \< 6 months. Pre-operative embolisation and intramedullary nail fixation with cement and helical blade.](eor-1-136-g007){#fig7-2058-5241.1.000008}

Bone metastases arising in the distal humerus are rare and present unique treatment challenges.^[@bibr47-2058-5241.1.000008]^ For actual fractures, intramedullary stabilisation will generally not provide sufficient stabilisation due to the anatomical localisation, thus plating with cement is advised. An impending fracture of the distal humerus can in most cases be treated with an intramedullary nail. Prosthetic reconstruction of the distal humerus rarely gives an adequate outcome and is associated with significant risks for complications and infections, and should not be pursued in a palliative setting.

Conclusions {#section10-2058-5241.1.000008}
===========

The treatment of patients with impending or actual pathological fractures of the long bones requires multi-disciplinary teamwork. Treatment highly depends on the fracture risk in relation to expected survival. Further individual tailoring is required to define the most optimal palliative strategy for each affected patient to maintain his or her quality of life.
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